Article

Kerry Fraser Talks Cancer Treatment

Author(s):

During an interview with the “CURE Talks Cancer” podcast, retired NHL referee Kerry Fraser discussed what it is like going through treatment for essential thrombocythemia.

During an interview with the “CURE Talks Cancer” podcast, retired NHL referee Kerry Fraser discussed what it is like going through treatment for essential thrombocythemia, including a bone marrow biopsy and daily chemotherapy pills.

As this blood cancer is incurable, ideally, Fraser said, his goal is to eventually die with this disease, not because of it.

CURE: MPN treatment can be very taxing. What were you treated with, and what was it like going through that treatment?

Fraser: Well I have essential thrombocythemia. They did the bone marrow biopsy, which was nothing, really. I had heard from people who said it's difficult and painful. They numbed it, and the doctor that was performing the procedure was being very delicate, and again, with this silly jock mentality, I said, "Listen, doc, go deep or go home. Let's get this sample and let's get out of here." He laughed and he gave it a little pop, and boy they got what they needed. From then on, it was clear sailing.

Things are in a good position for me through the chemo pill that I take. I take nine of them a week: one every day, two on Friday, two on Monday. It has reduced my platelet count at last blood test, a week or so ago. I'm at 285, which is in the normal range. So, we're managing this. My objective, and that of my doctor, is to die with this, and not because of it.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of doctor.
Image of man with black hair.
Picture of Dr. Pouneh Razavi
Richard Winneker gathers input from patients and researchers to shape MPN research, aiming to fund strategic projects for this population.
Dr. Curtiland Deville Jr. discusses the importance of crafting an individualized treatment plan for patients with prostate cancer.
Image of Crispino
Image of Dr. Reznick
Picture of Joy Anderson
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Anne M. Reb is a nurse practitioner with City of Hope.
Related Content